Expertise in
2
conditions

Dr. Mobeen H. Rathore

Pediatric Infectious Disease | Infectious Disease | Pediatrics
University Of Florida Jacksonville Physicians, Inc.
655 W 8th St, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
2
conditions
University Of Florida Jacksonville Physicians, Inc.
655 W 8th St, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mobeen Rathore is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Jacksonville, Florida. Dr. Rathore is highly rated in 2 conditions, according to our data. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Neonatal Herpes, HIV/AIDS, and H1N1 Influenza. Dr. Rathore is currently accepting new patients.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Infectious Disease
Infectious Disease
Pediatrics
Licenses
Pediatrics in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
View 1 Less Insurance Carrier -

Locations

UNIVERSITY OF FLORIDA JACKSONVILLE PHYSICIANS, INC.
655 W 8th St, Jacksonville, FL 32209
Other Locations
UNIVERSITY OF FLORIDA JACKSONVILLE PHYSICIANS, INC.
653 W 8th St, Ufjp Cardiology Department, Jacksonville, FL 32209
UNIVERSITY OF FLORIDA JACKSONVILLE PHYSICIANS, INC.
1443 San Marco Blvd, Jacksonville, FL 32207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drugs: Nucleoside Reverse Transcriptase Inhibitors, Nevirapine, Lopinavir+Ritonavir, Raltegravir, VRC01
Study Phase: Phase 1/Phase 2
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Other
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
Enrollment Status: Completed
Publish Date: June 27, 2025
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: Dolutegravir/Lamivudine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Enrollment Status: Completed
Publish Date: September 06, 2023
Intervention Type: Drug
Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study
Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study
Enrollment Status: Terminated
Publish Date: June 21, 2019
Intervention Type: Drug
Study Phase: Phase 4
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Device, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

69 Total Publications

Electronic Dose Monitoring Feedback (EMF) with Youth Living with HIV: Qualitative Exploration of Reactions to Viewing Dosing Calendars.
Electronic Dose Monitoring Feedback (EMF) with Youth Living with HIV: Qualitative Exploration of Reactions to Viewing Dosing Calendars.
Journal: AIDS and behavior
Published: June 26, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Tawana I. Thomas
Infectious Disease
Expertise in
30
conditions
Dr. Tawana I. Thomas
Infectious Disease

First Coast Infectious Disease Consultants LLC

2122 University Blvd S, 
Jacksonville, FL 
 (6.9 miles away)
904-398-5614
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tawana Thomas is an Infectious Disease provider in Jacksonville, Florida. Dr. Thomas has been practicing medicine for over 16 years is highly rated in 30 conditions, according to our data. Her top areas of expertise are Hospital-Acquired Pneumonia, Pneumonia, Sepsis, and Lymphangitis. Dr. Thomas is currently accepting new patients in some locations.

Expertise in
16
conditions
Dr. Omar K. Kawwaff
Infectious Disease
Expertise in
16
conditions
Dr. Omar K. Kawwaff
Infectious Disease
4123 University S Blvd A, 
Jacksonville, FL 
 (6.9 miles away)
904-733-8000
Languages Spoken:
English
See accepted insurances

Omar Kawwaff is an Infectious Disease provider in Jacksonville, Florida. Dr. Kawwaff is highly rated in 16 conditions, according to our data. His top areas of expertise are Sepsis, Osteomyelitis, Hospital-Acquired Pneumonia, and Osteomyelitis in Children.

Expertise in
21
conditions
Dr. Brian W. Cooper
Infectious Disease
Expertise in
21
conditions
Dr. Brian W. Cooper
Infectious Disease

First Coast Infectious Disease Consultants LLC

2122 University Blvd S, 
Jacksonville, FL 
 (6.9 miles away)
904-398-5614
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Cooper is an Infectious Disease provider in Jacksonville, Florida. Dr. Cooper is highly rated in 21 conditions, according to our data. His top areas of expertise are Hospital-Acquired Pneumonia, Sepsis, Cellulitis, and Pneumonia. Dr. Cooper is currently accepting new patients in some locations.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rathore's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile